1987 Volume 35 Issue Supplement2 Pages 413-417
Bacteriological and clinical studies on carumonam (CRMN), a new injectable monobactam monocyclic β-lactam) antibiotic, were carried out, and the following results were obtained.
1) Sensitivities of clinically isolated strains to CRMN were tested and compared with those of cefotiam (CTM), ceftizoxime (CZX) and aztreonam (AZT). Though CRMN and AZT were found to have no effect on Staphylococcus aureus, the activity of CRMN against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens and Proteus spp. was superior to AZT, peaking at 0.05 μg/ml for the MIC distribution-curve.
Activity against Pseudomonas aeruginosa ranged between 0.39-50 μg/ml of the MIC and was superior to AZT.
2) CRMN was administered to 6 patients with respiratory tract infection, at a dose of 1-2g twice a day for 3-9 days. The clinical effects were good in 2 cases, fair in 1 and poor in 3. The overall efficacy rate was 33.3%. No adverse reactions or abnormal findings in laboratory data were observed.
